INTERCURE overview

Revenues during the first half of 2024 reached NIS 126 million, alongside an Adjusted EBITDA 1 of NIS 21 million (Approximately 17% of revenues). Both quarters (Q1 and Q2 of 2024) ended with positive EBITDAs and profit from operations and represents InterCure’s 16 th and 17 th consecutive quarter of profitability 2 . Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza. InterCure is entitled to full compensation...

NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing...

NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “ Agreement ”) with the shareholders of Leon Pharm Ltd. (the “ Sellers ”, and “ Leon Pharm ” , respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain...

NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam...

NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security situation in the State of Israel, and its impact on the Company and its employees. On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border (the “ Israeli Southern Border ”) from the Gaza Strip...

Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023 Annualized revenue run rate of NIS 41 7 million ($ 149 million) Adjusted EBITDA 2 of NIS 30 million ($ 11 million) Generated NIS 35 million ($ 13 million) cash from operations in the second quarter Strong balance sheet with over NIS 116 million ($ 42 million) cash and financial assets 3 of NIS 71 million ($ 25 million) NEW YORK and HERZLIYA, Israel, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:...

NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Compan y "), announced today that its board of directors (“ Board ”) has approved the voluntarily delisting of the Company’s common shares (“ Shares ”) from the Toronto Stock Exchange (the “ TSX ”) (the “ Delisting ”). The Company has decided to delist from the TSX after concluding that maintaining the...

NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Compan y "), reports today that, further to the Company’s press release issued on February 1, 2023, where the Company had reported the termination of the merger agreement (the “ Agreement ”) with Cann Pharmaceutical Ltd. (" Better ") due to fundamental disagreements between the parties thereto and that the closing...